RxDoctor Payments Data

Angela Carrero, MD

Internal Medicine · Charlotte, NCNPI 1851662324

Payments from drug & device makers

$637in general payments, 2019–2025

Across 26 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$271
  • Novo Nordisk$120
  • AbbVie$56
  • Amarin Pharma, Inc.$55
  • Johnson & Johnson$29
  • Sanofi-aventis U.S. LLC$25
  • plus $81 from 5 others

What the payments were for

  • Food & beverage$637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$637 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,036
Medicare patients
143
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$47,239
MounjaroTirzepatide36$43,297
JardianceEmpagliflozin20$27,286
EliquisApixaban17$20,624
GemtesaVibegron13$8,006
SymbicortBudesonide/Formoterol Fumarate12$2,556
Rosuvastatin Calcium245$2,376
Levothyroxine Sodium201$1,741
Atorvastatin Calcium205$1,440
Ezetimibe57$1,402
SynthroidLevothyroxine Sodium13$1,359
Losartan Potassium149$1,036
Omeprazole81$923
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$719
Ketoconazole23$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$120$47,23943 claims
AstraZenecaSymbicort$271$2,55612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$1,741201 claims
AbbVieSynthroid$56$1,35913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →